Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

By Glassman Ar, Stock Cr, Beck Rw, C. Baker, Nguyen Qd, Brown Dm, Marcus Dm, Boyer Ds, Patel S Feiner, Gibson A Sy and 4 more. Ophthalmology (Rochester, Minn.), 2012

1,669 citations recorded by the source corpus.

Subfields: Ophthalmology

View Paper: https://www.semanticscholar.org/paper/6205da38b01f8ef40ce8fd171f8bc2ae57a4b66b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

1. V. Basevi

Citations in the corpus

• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial (2016, neutral): “(%) 5 (5) 8 (9) 2 (2) 3 ( 10 to þ3) P 1⁄4 0.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, neutral): “…studies has led to its approval for the treatment of other conditions as well: DME, (Phase III RESTORE trial 255 and Phase III RISE and RIDE trials 218 ); branch retinal vein occlusion (Phase III BRAVO trial 220 ); central retinal vein occlusion (Phase III CRUISE trial 220 ), choroidal…”
• Standards of Medical Care in Diabetes—2013 (2012, positive): “Recombinant monoclonal neutralizing antibody to VEGF is a newly approved therapy that improves vision and reduces the need for laser photocoagulation in patients with macular edema (372).”